NCT02791594View on ClinicalTrials.gov

Imaging FDG Flare in Melanoma

CompletedOBSERVATIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

July 1, 2020

Study Completion Date

July 1, 2020

Conditions
Metastatic Melanoma
Interventions
DRUG

Pembrolizumab

Patients were treated with pembrolizumab according to standard of care.

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02791594 - Imaging FDG Flare in Melanoma | Biotech Hunter | Biotech Hunter